5-[3-(2-羧基-4-氧代苯并吡喃-5-基)氧基-2-磺基氧基丙氧基]-4-氧代苯并吡喃-2-羧酸 | 107032-81-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 5-[3-(2-羧基-4-氧代苯并吡喃-5-基)氧基-2-磺基氧基丙氧基]-4-氧代苯并吡喃-2-羧酸
• 中文别名: ((3-(二(2-氯乙基)氨基)-4-甲基苯基)羟基甲烷)二膦酸
• 英文名称: Cromolyn sulfate
• 英文别名: 5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-sulfooxypropoxy]-4-oxochromene-2-carboxylic acid
• CAS: 107032-81-5
• 化学式: C₂₃H₁₆O₁₄S
• 分子量: 548.4
• InChiKey: KOMKRTNQZYEQST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  218
• 氢给体数：
  3
• 氢受体数：
  14

文献信息

• PYRROLIDINE DERIVATIVES AS SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
  申请人：Summit Corporation Plc

  公开号：US20140073801A1

  公开（公告）日：2014-03-13

  Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt, derivative, solvate, isomer, tautomer, N-oxide, ester, prodrug, isotope or protected form thereof, which are of use as OGA inhibitors, for example in the treatment of various conditions and diseases, including neurodegenerative disorders.

  公开了以下式（I）的化合物：或其药用盐、衍生物、溶剂合物、异构体、互变异构体、N-氧化物、酯、前药、同位素或其保护形式，这些化合物可用作OGA抑制剂，例如在治疗各种疾病和疾病，包括神经退行性疾病方面。
• [EN] PYRROLIDINE DERIVATIVES AS SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE PYRROLIDINE EN TANT QU'INHIBITEURS SÉLECTIFS DE GLYCOSIDASE ET LEURS UTILISATIONS
  申请人：SUMMIT CORP PLC

  公开号：WO2012117219A1

  公开（公告）日：2012-09-07

  Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt, derivative, solvate, isomer, tautomer, N-oxide, ester, prodrug, isotope or protected form thereof, which are of use as OGA inhibitors, for example in the treatment of various conditions and diseases, including neurodegenerative disorders.

  揭示了式(I)的化合物或其药用可接受的盐、衍生物、溶剂合物、异构体、互变异构体、N-氧化物、酯、前药、同位素或其保护形式，可用作OGA抑制剂，例如用于治疗各种疾病和症状，包括神经退行性疾病。
• Compositions and formulations of decitabine polymorphs and methods of use thereof
  申请人：Redkar Sanjeev

  公开号：US20060014949A1

  公开（公告）日：2006-01-19

  Pharmaceutical compositions and methods for treatment of neoplastic conditions using polymorphs of decitabine are provided. Also provided are methods for manufacturing and administering such pharmaceutical compositions.

  本发明提供了使用脱氧胞苷的多晶形态治疗肿瘤疾病的制药组合物和方法。同时还提供了制造和给药此类制药组合物的方法。
• Rapamycin for the treatment of lymphangioleiomyomatosis
  申请人：LAM Therapeutics, Inc.

  公开号：US10307370B2

  公开（公告）日：2019-06-04

  The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

  本发明涉及在需要治疗的人体中治疗淋巴管瘤病的方法和组合物。这些方法包括通过吸入向受试者施用包含雷帕霉素或其原药或衍生物（包括类似物）的气溶胶组合物。
• Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
  申请人：Lutonix, Inc.

  公开号：US10881644B2

  公开（公告）日：2021-01-05

  Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.

  本发明的实施方案提供了一种治疗呼吸系统疾病的方法，如哮喘、慢性阻塞性肺病和慢性鼻窦炎，包括囊性纤维化、间质纤维化、慢性支气管炎、肺气肿、支气管肺发育不良和肿瘤。 该方法包括服用消炎药和抗增生药（雷帕霉素或紫杉醇及其类似物）和添加剂，最好是口服、鼻饲或肺部服用。